CANTOS Trial Validates the Inflammatory Pathogenesis of Atherosclerosis: Setting the Stage for a New Chapter in Therapeutic Targeting

Circ Res. 2017 Oct 27;121(10):1119-1121. doi: 10.1161/CIRCRESAHA.117.311984.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review
  • Comment

MeSH terms

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Atherosclerosis*
  • Humans

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • canakinumab